The range of indications for our technologies extends well beyond our growing pipeline. We aim to commercialise our platform both through an active technology partnering strategy and by licensing our own therapeutic programs at the appropriate stage of development.
We welcome interest from pharmaceutical and biotechnology companies seeking access to our proprietary RNAi and delivery technology platform or to our therapeutic pipeline.
Research partnerships with top academic research institutions and commcercial partnerships leading pharmaceutical companies are a key component of our development strategy.
We believe that our comprehensive RNAi therapeutic platform can support and advance multiple partnerships across a diverse range of therapeutic opportunities. In particular, our broad range of delivery technologies allows us to offer potential partners a choice of solutions for the delivery of RNAi molecules to diseased tissue.
Some of our industry partners have included Quark, AstraZeneca, Dainippon Sumitmo Pharma, InteRNA, Mirna and miRagen.
Some of our current research collaborators include: Hanover Medical School, Marienhospital Herne University of Bochum, University Medicine Rostock, VU University Medical Centre Amsterdam, University of Birmingham and Oxford University.